ATE317849T1 - 5-hydroxysapogenin derivate mit aktivität gegen demenz - Google Patents

5-hydroxysapogenin derivate mit aktivität gegen demenz

Info

Publication number
ATE317849T1
ATE317849T1 AT00964452T AT00964452T ATE317849T1 AT E317849 T1 ATE317849 T1 AT E317849T1 AT 00964452 T AT00964452 T AT 00964452T AT 00964452 T AT00964452 T AT 00964452T AT E317849 T1 ATE317849 T1 AT E317849T1
Authority
AT
Austria
Prior art keywords
hydroxysapogenin
derivatives
activity against
against dementia
dementia
Prior art date
Application number
AT00964452T
Other languages
English (en)
Inventor
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Application granted granted Critical
Publication of ATE317849T1 publication Critical patent/ATE317849T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT00964452T 1999-09-29 2000-09-29 5-hydroxysapogenin derivate mit aktivität gegen demenz ATE317849T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923078.1A GB9923078D0 (en) 1999-09-29 1999-09-29 Sapogenin derivatives and their use

Publications (1)

Publication Number Publication Date
ATE317849T1 true ATE317849T1 (de) 2006-03-15

Family

ID=10861839

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964452T ATE317849T1 (de) 1999-09-29 2000-09-29 5-hydroxysapogenin derivate mit aktivität gegen demenz

Country Status (14)

Country Link
US (3) US20030100542A1 (de)
EP (1) EP1224207B1 (de)
JP (1) JP2003525869A (de)
CN (1) CN1377366A (de)
AT (1) ATE317849T1 (de)
AU (1) AU7538700A (de)
BR (1) BR0014372A (de)
CA (1) CA2385440C (de)
DE (1) DE60026046T2 (de)
ES (1) ES2257321T3 (de)
GB (1) GB9923078D0 (de)
HK (1) HK1045524B (de)
MX (1) MXPA02003307A (de)
WO (1) WO2001023408A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
CN100430062C (zh) * 2002-03-15 2008-11-05 萨马里坦药品公司 神经保护性螺甾烯醇药用组合物
DE60326437D1 (de) * 2002-03-27 2009-04-16 Phytopharm Plc Godmanchester Therapeutische verwendung von sapogeninen
KR20100093621A (ko) * 2002-03-27 2010-08-25 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 용도
JP4573157B2 (ja) * 2002-03-27 2010-11-04 フィトファーム・パブリック・リミテッド・カンパニー 治療方法ならびにサポゲニンおよびその誘導体の使用
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
WO2010084356A1 (en) 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
AU2011281336B2 (en) 2010-07-20 2015-03-05 Junaxo, Inc. Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US11319338B2 (en) 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
KR101777920B1 (ko) * 2015-07-27 2017-09-14 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852847A (en) * 1958-03-04 1960-11-02 British Drug Houses Ltd Improvements in or relating to 6-methyl steroid compounds
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
WO1991010743A1 (en) * 1990-01-18 1991-07-25 Cura Nominees Pty Ltd Glycoalkaloids
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
US5629295A (en) * 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
CN1102186A (zh) * 1993-10-29 1995-05-03 沈阳医学院 中药薤白新成分的鉴定及用途
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
EP0737202A1 (de) * 1993-12-28 1996-10-16 Pfizer Inc. Hypocholesterolemische mittel
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
FI970828L (fi) * 1994-08-30 1997-02-27 Pfizer Spirostanyyliglykosidien kiteitä
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
CU22860A1 (es) * 1995-10-12 2003-05-26 Univ La Habana Espirostanonas con funciones oxigenadas en el anillo a. como reguladores del crecimiento vegetal y su procedimiento de obtención
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
CN1245982C (zh) * 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
US20030118673A1 (en) * 1998-03-26 2003-06-26 Zongqin Xia Smilagenin and anzurogenin-D for the treatment of alzheimer's disease
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
AU762302B2 (en) * 1998-05-04 2003-06-19 Pfizer Products Inc. 2"-deoxy hygromycin derivatives
GT199900064A (es) * 1998-05-04 2000-10-24 Pfizer Prod Inc Derivados de higromicina a.
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
DK1083889T3 (da) * 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
KR100818845B1 (ko) * 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
CA2355075C (en) * 1998-12-16 2009-12-08 Aventis Pharma Limited Heteroaryl-cyclic acetals
CO5150194A1 (es) * 1999-01-27 2002-04-29 Abbott Lab Inhibidores hidroxamato inversos de las metalopreteinasas matriciales
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
GB9919957D0 (en) * 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
BR0001794A (pt) * 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
US6500839B2 (en) * 2000-05-18 2002-12-31 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Also Published As

Publication number Publication date
DE60026046T2 (de) 2006-10-05
DE60026046D1 (de) 2006-04-20
US20030100542A1 (en) 2003-05-29
HK1045524B (en) 2006-05-12
MXPA02003307A (es) 2002-10-04
WO2001023408A1 (en) 2001-04-05
US20080020021A1 (en) 2008-01-24
BR0014372A (pt) 2002-06-25
CA2385440C (en) 2008-05-20
JP2003525869A (ja) 2003-09-02
CA2385440A1 (en) 2001-04-05
ES2257321T3 (es) 2006-08-01
GB9923078D0 (en) 1999-12-01
HK1045524A1 (en) 2002-11-29
CN1377366A (zh) 2002-10-30
US20060165757A1 (en) 2006-07-27
EP1224207A1 (de) 2002-07-24
AU7538700A (en) 2001-04-30
EP1224207B1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
DE60137307D1 (de) Substituierte sapogenine und ihre verwendung
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE514676T1 (de) Ionisierbare indolinon derivate und deren verwendung als ptk liganden
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR200402628T4 (tr) Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
CA2385410A1 (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
DE50003761D1 (de) Indeno-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69604071D1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE420074T1 (de) Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen
MY134920A (en) 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1224207

Country of ref document: EP

REN Ceased due to non-payment of the annual fee